Overview

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Status:
RECRUITING

Trial end date:
2031-08-31

Target enrollment:

Participant gender:

Summary

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Phase:

PHASE3

Details

Lead Sponsor:

Amgen

Treatments:

Bevacizumab
Panitumumab
sotorasib